-
New markers for a variety of diseases have recently received considerable attention, specifically B-type natriuretic peptide (BNP), N-terminal-pro-BNP, C-reactive protein, or CRP, and CRP-hs (high sensitivity). Levels of these compounds are useful guides in assessing the severity of important medical conditions, such as congestive heart failure and acute myocardial infarction chest pain.
-
Syncope is commonly accepted to be a danger sign in patients with hypertrophic cardiomyopathy (HCM). In this paper, Spirito et al report data from a registry of 1,511 patients with HCM who have been followed longitudinally at four institutions.
-
It has been postulated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II-receptor blockers (ARBs) decrease the risk of developing atrial fibrillation both indirectly by better control of hypertension and heart failure and directly by effects on fibrosis,
-
NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.
-
Patients presenting to the emergency department (ED) with acute chest pain are a significant portion of our health care budget. Current recommendations for the assessment and management of these patients involve extended periods of observation for repeated biomarkers and electrocardiograms (ECG). This often results in hospital admission to "rule out" myocardial infarction. Any advance in the speed or accuracy of diagnosis of the cause of chest pain, or to rule out myocardial ischemia as the cause, would be a significant clinical advance.
-
-
Heart failure (HF), the end result of many cardiovascular disorders and a common disabling clinical syndrome, affects almost 6 million people in the United States.
-
A brief intervention of an extract of ginger administered four times daily was effective in ameliorating nausea and vomiting of pregnancy in this small single-blind trial.
-
Upon evaluating data from the STAR*D project, researchers concluded that phase III clinical trials often do not recruit representative populations of depressed outpatients, making the recommendations drawn from the studies' conclusions of limited applicability to general clinical practice.
-
This small pilot study represents the first controlled assessment of intravenous micronutrient therapy for fibromyalgia. No statistically significant benefit over placebo was identified, though clinical benefit was apparent, and feasibility was established. Regardless of one's bias regarding this type of care, further study is needed.
